Memantine

Speaker 1...and that brings us to memantine, an NMDA antagonist often used to manage chronic pain. It's an interesting case because, while pain itself can definitely impact aging, there are questions about memantine’s long-term effects on biological aging and all-cause mortality.

Speaker 2Exactly. The evidence suggests unrelieved pain, like diabetic neuropathy, accelerates epigenetic aging and telomere shortening. A study in *GeroScience* in 2025, for example, PMID 39847262, found painful diabetic neuropathy was linked to accelerated epigenetic aging compared to painless neuropathy. So, treating pain is crucial.

Speaker 1Right. But then we weigh that against what we know, and don't know, about memantine's long-term use. While it can offer significant relief for some, particularly in supervised settings for specific conditions, its direct impact on slowing or accelerating biological aging markers or affecting all-cause mortality in the general population isn't established.

Speaker 2That’s key. There isn't robust evidence to suggest memantine *slows* biological aging or *reduces* all-cause mortality. And like any medication, it has potential side effects, including dizziness, confusion, and falls, particularly in older adults, which could indirectly affect quality of life and even mortality risk.

Speaker 1So, for individuals with chronic pain, the decision to use memantine involves carefully balancing the known benefits of pain relief against these potential long-term uncertainties and specific side effect risks. It’s a personalized medical decision, always with a healthcare provider. We're talking about the scientific landscape here, not individual medical advice.

Speaker 2Absolutely. The research on its direct role in biological aging beyond pain relief is still very much an open question, and definitely not a reason to stop a prescribed treatment without medical consultation.